Current Management of Gallbladder Carcinoma

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2010 Feb 12

PMID 20147507

Citations 154

Authors

Andrew X Zhu

Theodore S Hong

Aram F Hezel

David A Kooby

Affiliations

Soon will be listed here.

Abstract

Gallbladder cancer (GBC) represents the most common and aggressive type among the biliary tree cancers (BTCs). Complete surgical resection offers the only chance for cure; however, only 10% of patients with GBC present with early-stage disease and are considered surgical candidates. Among those patients who do undergo "curative" resection, recurrence rates are high. There are no established adjuvant treatments in this setting. Patients with unresectable or metastatic GBC have a poor prognosis. There has been a paucity of randomized phase III data in this field. A recent report demonstrated longer overall survival with gemcitabine in combination with cisplatin than with gemcitabine alone in patients with advanced or metastatic BTCs. Molecularly targeted agents are under development. In this review, we attempt to discuss the current status and key issues involved in the management of GBC.

Citing Articles

Epidermal Growth Factor Receptor (EGFR) and SMAD4 negatively correlated in the progression of gallbladder cancer in Eastern Indian patients.

Choudhury S, Ghosh S, Chakraborty P, Pal S, Ghosh K, Saha S BMC Gastroenterol. 2024; 24(1):446.

PMID: 39623311 PMC: 11613908. DOI: 10.1186/s12876-024-03485-4.

The usefulness of B-cell lymphoma-2 immunohistochemical stain in the differentiation between reactive atypia and dysplasia/carcinoma in the gallbladder.

Alkhamiss A Int J Health Sci (Qassim). 2024; 18(6):20-24.

PMID: 39502427 PMC: 11533188.

A Single-Center Analysis of Patient Characteristics and Overall Survival in Patients with Resectable Gallbladder Cancer.

Ozturk N, Dadamyan A, Jamil L Healthcare (Basel). 2024; 12(20).

PMID: 39451505 PMC: 11507044. DOI: 10.3390/healthcare12202091.

Gallbladder cancer: Progress in the Indian subcontinent.

Kumar A, Sarangi Y, Gupta A, Sharma A World J Clin Oncol. 2024; 15(6):695-716.

PMID: 38946839 PMC: 11212610. DOI: 10.5306/wjco.v15.i6.695.

Prognostic Insights and Survival Analysis of Gallbladder Cancer in Bihar, India: a Prospective Observational Study Emphasizing the Impact of Surgical Intervention on Overall Survival.

Singh D, Singh P, Mandal A, Rakesh A Indian J Surg Oncol. 2024; 15(Suppl 2):196-203.

PMID: 38817991 PMC: 11133252. DOI: 10.1007/s13193-024-01925-x.

References

Ramanathan R, Belani C, Singh D, Tanaka M, Lenz H, Yen Y . A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009; 64(4):777-83. DOI: 10.1007/s00280-009-0927-7. View

Misra S, Chaturvedi A, Misra N, Sharma I . Carcinoma of the gallbladder. Lancet Oncol. 2003; 4(3):167-76. DOI: 10.1016/s1470-2045(03)01021-0. View

Mojica P, Smith D, Ellenhorn J . Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. J Surg Oncol. 2007; 96(1):8-13. DOI: 10.1002/jso.20831. View

Kawamoto T, Krishnamurthy S, Tarco E, Trivedi S, Wistuba I, Li D . HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer. Gastrointest Cancer Res. 2009; 1(6):221-7. PMC: 2631213. View

Todoroki T, Kawamoto T, Otsuka M, Koike N, Yoshida S, Takada Y . Benefits of combining radiotherapy with aggressive resection for stage IV gallbladder cancer. Hepatogastroenterology. 1999; 46(27):1585-91. View

Jarnagin W, Gonen M, Fong Y, DeMatteo R, Ben-Porat L, Little S . Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002; 236(4):397-406; discussion 406-7. PMC: 1422593. DOI: 10.1097/01.SLA.0000029003.66466.B3. View

Jarnagin W, Ruo L, Little S, Klimstra D, DAngelica M, DeMatteo R . Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003; 98(8):1689-700. DOI: 10.1002/cncr.11699. View

Hong Y, Lee J, Lee S, Hwang I, Choi S, Heo J . Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer Chemother Pharmacol. 2006; 60(3):321-8. DOI: 10.1007/s00280-006-0380-9. View

Suzuki S, Yokoi Y, Kurachi K, Inaba K, Ota S, Azuma M . Appraisal of surgical treatment for pT2 gallbladder carcinomas. World J Surg. 2004; 28(2):160-5. DOI: 10.1007/s00268-003-7080-y. View

10.

Takada T, Kato H, MATSUSHIRO T, Nimura Y, Nagakawa T, Nakayama T . Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology. 1994; 51(5):396-400. DOI: 10.1159/000227373. View

11.

Frena A, La Guardia G, Martin F . Outcome of radical surgery for carcinoma of the gallbladder according to the tumor node metastasis and Japanese Society of Biliary Surgery stages. J Gastrointest Surg. 2004; 8(5):580-90. DOI: 10.1016/j.gassur.2003.11.011. View

12.

Fong Y, Jarnagin W, Blumgart L . Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg. 2000; 232(4):557-69. PMC: 1421188. DOI: 10.1097/00000658-200010000-00011. View

13.

Wistuba I, Gazdar A . Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004; 4(9):695-706. DOI: 10.1038/nrc1429. View

14.

Endo I, Shimada H, Tanabe M, Fujii Y, Takeda K, Morioka D . Prognostic significance of the number of positive lymph nodes in gallbladder cancer. J Gastrointest Surg. 2006; 10(7):999-1007. DOI: 10.1016/j.gassur.2006.03.006. View

15.

Shirai Y, Yoshida K, Tsukada K, Muto T, Watanabe H . Radical surgery for gallbladder carcinoma. Long-term results. Ann Surg. 1992; 216(5):565-8. PMC: 1242674. DOI: 10.1097/00000658-199211000-00007. View

16.

Dixon E, Vollmer Jr C, Sahajpal A, Cattral M, Grant D, Doig C . An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg. 2005; 241(3):385-94. PMC: 1356976. DOI: 10.1097/01.sla.0000154118.07704.ef. View

17.

Wise P, Shi Y, Washington M, Chapman W, Wright J, Sharp K . Radical resection improves survival for patients with pT2 gallbladder carcinoma. Am Surg. 2001; 67(11):1041-7. View

18.

Meyerhardt J, Zhu A, Stuart K, Ryan D, Blaszkowsky L, Lehman N . Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci. 2007; 53(2):564-70. DOI: 10.1007/s10620-007-9885-2. View

19.

Kai M, Chijiiwa K, Ohuchida J, Nagano M, Hiyoshi M, Kondo K . A curative resection improves the postoperative survival rate even in patients with advanced gallbladder carcinoma. J Gastrointest Surg. 2007; 11(8):1025-32. DOI: 10.1007/s11605-007-0181-4. View

20.

Gwak G, Yoon J, Shin C, Ahn Y, Chung J, Kim Y . Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol. 2005; 131(10):649-52. DOI: 10.1007/s00432-005-0016-1. View